Oral and poster presentations of Gilead and Kite-sponsored studies at the 65th ASH Annual Meeting and Exposition in San Diego, California

Our pipeline includes various targets and approaches in oncology today, from antibody-drug conjugates and small molecules to cell therapy-based approaches.

The result of this approach is a portfolio that includes many assets with complementary mechanisms of action and strong potential to span diverse tumor types and lines of therapy, both on their own and in combinations.

We are commited to patients living with blood cancer.
Explore ongoing trials, enrolling trials, and MoAs our trials are investigating.

We are commited to patients living with breast cancer.
Explore ongoing trials, enrolling trials, and MoAs our trials are investigating.

We are commited to patients living with lung and thoracic cancer.
Explore ongoing trials, enrolling trials, and MoAs our trials are investigating.

We are commited to patients living with GU/GI/GYN cancer.
Explore ongoing trials, enrolling trials, and MoAs our trials are investigating.